Background-Current immunosuppressive therapy after heart transplantation either generally suppresses the recipient's entire immune system or is mainly targeting Tlymphocytes. Monocytes/macrophages are recognized as a hallmark of acute allograft rejection, but the roles that they play are not well characterized in vivo, because the tools for accessing in situ macrophage infiltration are lacking. In this study, we used MRI to investigate the role of macrophages in acute heart allograft rejection by cellular and functional MRI with selectively depleted systemic macrophages without affecting other leukocyte population, as well as to explore the possibility that macrophages could be an alternative therapeutic target. Methods and Results-A rodent heterotopic working heart-lung transplantation model was used for studying acute allograft rejection. Systemic macrophages were selectively depleted by treating recipient animals with clodronateliposomes.
M acrophage infiltration has long been recognized as a hallmark of acute allograft rejection after heart transplantation; however, the discrete roles of macro phages during the onset and evolution of rejection are not fully understood. 1 Recent reports on various inflammation processes, such as myocardial infarction, cancer, and renal allograft rejection, have revealed that macrophages can play complicated and even conflicting roles. Macrophages have been shown to both increase tissue injury and promote tissue repair, depending on the macrophage phenotype and timing of recruitment.
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To better understand the role of macrophages in rejection, it is necessary to longitudinally and concurrently monitor the macrophage infiltration and graft function as rejection evolves, to examine if they contribute solely in a harmful way, are involved in repairing and functional preservation, or are just innocent bystanders, 1 without playing any critical role. Noninvasive clinical tools for assessing in situ macrophage infiltration on the rejecting sites are lacking. The goal of this study was to investigate whether macrophages play a key role in acute cardiac allograft rejection, using serial noninvasive assessment with cellular and functional MRI.
We have previously shown that cardiac allograft rejection can be detected and graded in vivo with both cellular and functional cardiac MRI. 5, 6 In situ macrophage infiltration in rejecting grafts can be evaluated noninvasively and longi tudinally over time by labeling monocytes/macrophages in circulation with contrast agents, such as ultrasmall super paramagnetic iron oxide (USPIO) particles. USPIOlabeled macrophages are observed by T 2 *weighted MRI, and the amount detected is associated with the degree of rejection. 5, 6 We have also demonstrated that cardiac MRI, particularly tag ging followed by strain analysis, provides a sensitive measure for evaluating the functional loss as a result of acute allograft rejection. Furthermore, the regions with high macrophage infiltration correlate well with functional impairment. 6 In this study, we used a rodent heterotopic cardiac trans plantation model 6 and liposomeencapsulated clodronate to deplete circulating monocytes/macrophages selectively. 7, 8 This model allowed us to study the progression of cardiac rejection from early onset to the most severe case, with com plete loss of graft function. This study had 2 objectives: first, to examine whether eliminating monocytes/macrophages in circulation can reduce macrophage populations found in the rejecting graft; and second, to investigate how reducing macrophage populations affect the progression or severity of rejection and loss of cardiac function.
Methods Animals
All animals used in this study were male inbred Brown Norway (BN; RT1 n ) and Dark Agouti (DA; RT1 a ) rats obtained from Harlan, Indianapolis, IN, with body weight ≈250 g. Animal protocols were approved by the Institutional Animal Care and Use Committee of Carnegie Mellon University. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health.
Animal Model
This study used a rodent heterotopic working heart-lung transplanta tion model in the abdomen, which has been described in detail else where. 6 DAtoBN allograft transplantation results in grade I rejection on postoperational days (PODs) 3 to 4, grade II rejection on PODs 4 to 5, grade III rejection on PODs 5 to 6, and all grafts are severely rejected (grade IV) by POD 7. Many allograft hearts stop beating on POD 7, and none can survive past POD 8 without intervention.
DAtoBN allografts were assigned to 1 of 3 groups: receiving clodronateliposome treatment (n=17); receiving PBSliposome treatment (n=11); or allografts receiving no treatment (n=10). Additionally, BNtoBN transplantation (n=4) served as isograft controls. Clodronateliposomes and control PBSliposomes were obtained from http://clodronateliposomes.org and their preparation has been described elsewhere. 8 Both were administered as a bolus of 1mL liposome suspension via tail vein on PODs 1, 3, 6, and 8 after transplant surgery. This resulted in a clodronate dose of 28 mg/kg.
At the end point of the study, ranging from PODs 7 to 9, organs were harvested and fixed in 4% paraformaldehyde for 24 hours, fol lowed by storage in PBS at 4°C.
In Vivo Labeling of Macrophages With USPIO Nanoparticles
Dextrancoated USPIO nanoparticles were used to label macrophages in vivo for cellular MRI. USPIO particles used were either synthe sized in our laboratory 9 or purchased from BioPAL, Worchester, MA (Molday ION). Molday ION purchased from BioPAL (http://www. biopal.com/moldayion.htm) and USPIO nanoparticles synthesized in our laboratory 9 are both dextrancoated iron oxide particles and exhibit similar biophysical and magnetic properties, such as hydro dynamic diameter, zeta potential, and relaxivity. Each animal was given USPIO (4.5 mg iron per kilogram body weight) intravenously as bolus via tail vein ≈20 to 24 hours before the first MRI session on POD 4 and was imaged daily up to POD 9. The blood halflife of USPIO particles in rodents is ≈2 hours. 10 Each animal was given sufficient time (≥5 USPIO blood halflife) to allow the USPIO particles to be cleared before MRI sessions; thus, labeling efficiency and levels should be similar among animals.
Flow Cytometry
Flow cytometry was used to determine the percentage of mono cytes/macrophages, lymphocytes, and natural killer cells in periph eral blood (FACSVantage; Becton Dickinson, Franklin Lakes, NJ). Blood samples were taken from untreated allotransplant rats (n=6), PBSliposome-treated allotransplant rats (n=5), and clodronateli posome-treated allotransplant rats (n=6) before euthanization. 
Magnetic Resonance Imaging
In vivo MRI was performed on a Bruker BioSpec AVANCE III 7T/21cm system equipped with a BGA12S gradient set and a 72 mm birdcage RF coil (Bruker Biospin Billerica, MA). Rats were intu bated and ventilated as described previously. 5, 6 Core temperature was maintained at 36.8±0.5°C with a gating and monitoring system (SA Instruments, Stony Brook, NY). ECG leads were placed on the abdo men to detect the waveform of the transplanted heart. T 2 *weighted images were acquired with a FLASH sequence, and tagging was achieved using SPAMM. 11, 12 Nine shortaxis slices were used to cover the entire volume of the heart for T 2 *weighted imag ing, and a single shortaxis slice at midventricular level was used for tagging. Both ECG and respiration triggers were used for gated imag ing. The Rwave of ECG was used for cardiac MR trigger. Multiple slices of images were acquired within a repetition time (TR), which was set to be equal to a cardiac cycle, ≈180 to 200 ms. Although TR was set to be the cardiac cycle, with respiration gating (60 bpm) the effective TR for MR image acquisition was 1 second. Images were acquired with the following parameters: TR=respiration cycle (≈1 second); echo time (TE), 2.7 ms for tagging MRI, and 5 to 7 ms for T 2 *weighted imaging; flip angle, 30° for T 2 *weighted imaging and 15° for tagging; field of view, 4 cm, slice thickness, 1.2 to 1.5 mm, with 156 µm inplane resolution.
Graft hearts were harvested at the end point of the study and fixed in 4% paraformaldehyde. Fixed hearts were imaged using a Bruker AVANCE DRX 11.7T system with a Micro2.5 gradient in sert. Highresolution 3dimensional (3D) MR microscopy (MRM) images were acquired with a TR/TE=480/5.5 ms and a 46 to 49 µm isotropic resolution.
Strain and Wall-Motion Analysis
Strains are values that quantify the extent of ventricular deformation throughout cardiac phases: stretching/elongation or compression/ shortening. Strains can be classified into 2 main classes in relation to the heart axes: normal strains are defined in relation to the short axis planes, and principal strains are defined in relation to the direction of myocardial fiber bundles. There are 3 types of straintensor sets for each class. Two of the 3 orthogonal straintensor sets, circumferential shortening (Ecc) and radial strain (Err), are presented in this study. HARP (Diagnosoft, Inc, Morrisville, NC) was used for the tagged MRI strain analysis. 13, 14 DICOM images of the tagged MRI time se ries were imported in HARP software, Fouriertransformed, then ana lyzed by the HARP method.
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3D MRM Rendering and Visualization
Image voxels showing hypointensity were identified from the 3D volume stack using a signal intensity threshold calculated automati cally by the Otsu method, 15 which maximized the variance between the hyper and hypointensity voxels. Voxels with hypointensity were then represented with the red color. Movie files showing each of the 3D volume rendering sets orbiting through the central axis for better unbiased visualization are shown in Figure I in onlineonly Data Supplement.
Pathological Analysis and Rejection Grade Evaluation
Histopathology was performed by the Transplantation Pathology Laboratory of the University of Pittsburgh Medical Center. Graft tis sues were subjected to hematoxylin and eosin (H&E) staining and immunohistochemical staining with the mouse antirat macrophage antibody ED1 (AbD Serotec) for detecting macrophages, and antirat Tcell antibody CD3 for detecting Tcells. Rejection grade of the grafts was determined histopathologically according to the International Society for Heart and Lung Transplantation (ISHLT) criteria. 16 
Statistical Analysis
Descriptive statistics for leukocytes data were presented as median and interquartile range. Examination of normal distribution assumption for leukocytes data was determined byplots, histograms, and ShapiroWilk test. For nonnormal distributed data, a Kruskal-Wallis test was performed to test an overall hypothesis of any difference between the 3 groups (ie, PBSliposome, clodronateliposome, and no treatment) for each leukocyte at POD 7. Adjustment for multiple hypotheses testing (6 hypotheses) was performed using the Holm method. If the overall test was significant, post hoc comparisons were performed us ing the Mann-Whitney test and adjustment for multiple comparisons was performed using the Dunn-Sidak adjustment method. 17 Adjusted P values for multiple hypotheses testing and for post hoc comparisons were presented. For the strain data, linear mixedeffects models were used to test the main effects of time (POD 5, 6, 7, 8, and 9) and group (PBSliposome, clodronateliposome, and no treatment), and time by group interactions on Ecc and Err separately, and to account for within subject correlation. One betweensubject factor (group) and 1 within subject factor (time) and their interaction were defined as fixed effects, and the subject as random effect. After inspecting the correlation within subjects and the autoregressive structure for Ecc, a compound sym metry structure for Err was assumed. The least significant difference method was used for post hoc comparisons using the Sidak adjustment method. Adjusted P values for post hoc comparisons were presented. All statistical analyses were 2sided, and the significance value was P<0.05. All analyses were conducted using SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC). Tables I and II in the online only Data Supplement summarize our statistical data.
Results
Clodronate-Liposome Treatment Selectively Depleted Monocytes/Macrophages
After clodronateliposome treatment, ED1
+ monocytes/macro phages are reduced by >90% in blood circulation ( Figure 1 
Fewer Macrophages Found in Treated Allografts
After labeling macrophages with USPIO particles, in vivo T 2 *weighted images of an untreated transplant recipi ent ( Figure 2B ) and PBSliposome-treated allograft heart ( Figure 2D) show regions of hypointensity in the rejecting allograft heart, indicating the accumulation of USPIOlabeled macrophages. Consistent with diminishing the macrophage infiltration into the graft heart, the clodronatetreated allograft heart ( Figure 2C ) displays little or no area of hypointensity. Figure 3 shows slices from 3D T 2 *weighted MRM of excised hearts (Figure 3 , upper panels) and the 3D volume renderings (Figure 3 , lower panels) of untreated ( Figure 3A and 3G), clodronateliposome-treated ( Figure 3C and 3I) , and PBSliposome-treated ( Figure 3E and 3K) allograft hearts. Both untreated and PBSliposome-treated groups have significant USPIOlabeled macrophage infiltration. USPIOlabeled macrophage infiltration is greatly reduced in the clodronateliposome-treated allogaft hearts, although this is still low level of USPIOlabeled macophages observed. All the native hearts ( Figure 3B , 3D, 3F, 3H, 3J, 3L) from the same treated animals have little USPIOlabeled accumula tion, indicating that the macrophage infiltration into reject ing allograft hearts is specific and selective.
Immunohistochemical staining of the allograft hearts (Figure 4 ) confirms the cellular MRI finding. Both untreated ( Figure 4A ) and PBSliposome controls ( Figure 4B ) exhibit significantly more ED1 + macrophage infiltration on POD 7 compared with clodronateliposome-treated heart ( Figure 4C ).
Reducing Macrophage Infiltration Resulting in Preserved Tissue Integrity
Graft tissue integrity is evaluated with H&E tissue staining ( Figure 5 ). On POD 7, as rejection progresses to a more severe stage, untreated allografts ( Figure 5B ) lose myocardium integ rity with visible cellular infiltration. No untreated allografts can sustain past POD 8. On the contrary, the clodronatelipo some-treated allografts show a marked improvement in tis sue integrity on POD 7 ( Figure 5C ), similar to the isografts ( Figure 5A ) with no rejection. By POD 9 ( Figure 5D ), the clodronateliposome-treated allografts start to show signs of acute rejection, exhibiting increased infiltration of mononu clear cells and tissue injury.
Reducing Macrophage Infiltration Resulting in Preserved Cardiac Function
To assess whether reducing only 1 cell type, macrophages, without affecting other immune cells is sufficient to attenu ate acute allograft rejection, we have examined the functional consequences of clodronateliposome treatment. We have shown that strain values derived from myocardialtagged MRI can best differentiate regional wallmotion changes result ing from acute allograft rejection.
6 Figure 6 shows Ecc maps derived from the tagged MRI of an untreated ( Figure 6A ), a PBSliposome-treated ( Figure 6B) , and a clodronatelipo some-treated ( Figure 6C ) allograft heart over time. With no treatment, allograft hearts undergo normal progression of acute rejection over time ( Figure 6A and 6D, blue circles), exhibiting a sharp decrease in left ventricle wall motion. The clodronateliposome-treated allograft hearts ( Figure 6C and 6D, red squares) exhibit improved wall motion from POD 5 to 6; myocardial areas with mediumtohigh strain values increase, and subsequent functional loss from POD 7 to 9 is significantly less. In the PBSliposome-treated allograft heart ( Figure 6B and 6D, green triangles), although showing slight improvement in function early on, the cardiac function also degrades sharply after POD 6. Conversely, clodronateliposome-treated allograft hearts exhibit improved strain and cardiac function in the early phase and then a decrease in function later. The vast majority of untreated allograft hearts lose function with no detectable ECG on POD 7, and none can sustain past POD 8. PBSliposome-treated allografts also undergo functional deterioration over time, but the progress of the dysfunction follows a slower time course, compared with that of untreated group. On POD 7, when most untreated allografts are not functional, PBSliposome-treated allografts still preserve cardiac function that is comparable to clo dronateliposome-treated allografts. However, PBSliposometreated allograft hearts continue to lose contractility, and by POD 9, they have become not functional, with no meaningful strain values detected. On the contrary, clodronateliposome-treated allograft hearts preserve wall motion with little or no decline up to POD 7 and still maintain >80% of the strain values on POD 9. There was no statistically significant difference in the strains for clodronateliposome-treated hearts between PODs 7 and 9 (Ecc P=0.6689; Err P=0.8533), but both circumferential and radial strains showed significant differences between clodronatelipo some-treated and PBSliposome-treated hearts (Ecc P=0.0289; Err P=0.0009) on POD 9.
Our results demonstrate that clodronateliposome treatment can preserve cardiac tissue integrity and cardiac function in acute allograft rejection. This indicates that clodronatelipo some treatment significantly alters the progression of acute rejection in allograft hearts, and that macrophages play a sig nificant role in the progression of acute rejection.
Discussion
After transplantation, patients must endure a lifelong regi men of immunosupression therapy. Despite the medical advancement, allograft rejection remains a threat to long term survival, and new therapeutic methods and monitoring strategies to improve and personalize treatment are much needed. The current immunosupression therapy is mainly focused on blocking Tlymphocytes or general broadband immune suppression. In this study, we have looked at the specific effects of macrophages on cardiac allograft rejec tion by selectively depleting macrophages with intravenous injections of clodronateencapsulated liposomes. 7, 8 It has been reported that this strategy is effective for delaying rejec tion in rat corneal allografts, 18, 19 pig pancreas xenografts, 20, 21 liver transplantation, 22 and rat renal allografts 23 ; however, its use in cardiac transplantation has not yet been studied. Our approach to monitor cellular infiltration and cardiac function simultaneously by MRI provides a good platform to moni tor noninvasively the immune cell infiltration and functional consequences longitudinally over time.
We have previously demonstrated that standard cardiac MRI protocols, such as cine imaging and global systolic functional parameters derived from cine, ejection fraction, Figure 3 . Clodronate-liposome treatment reduces macrophage infiltration in the rejecting allograft hearts, evaluated by ex vivo T 2 *-weighted 3-dimensional (3D) MR microscopy (MRM). A to F, 1 2D image from the 3D MRM image stacks. G to L, 3D volume rendering, with hypointensity shown in red color, of no treatment allograft heart (A and G), clodronate-liposome-treated allograft heart (C and I), and PBS-liposome-treated allograft heart (E and K), as well as native hearts from the same no treatment animal (B and H), clodronateliposome-treated animal (D and J), PBS-liposome-treated animal (F and L). T 2 *-weighted MRM was acquired at 11.7 T with 46 to 49 μm isotropic resolution. or stroke volume, are not sensitive in discriminating reject ing allograft hearts from nonrejecting isografts, especially in the earlier rejection stages. 6 We have shown that myocardial strains derived from tagging MRI are sensitive and accurate parameters that can better quantify various rejection grades in acute allograft rejection. 6 Because the focus of this study was to investigate the effects of clodronateliposomes on cardiac function in allograft rejection, we have used the cardiac MRI parameters, strains derived from tagging MRI, for best assess ing allograft rejection.
In the rat transplantation model used in this study, we have previously demonstrated that the BNtoBN isograft hearts (with no rejection) exhibited wall motion and strain values comparable to those of native hearts, although stroke volume was somewhat less. 6 Graft hearts in this model preserve intact pulmonary circulation, and all 4 heart chambers exhibit wall motion and strains close to native hearts 6 and show similar pathological features as human transplanted hearts determined histopathologically according to the updated ISHLT criteria for human patients. 24 In addition, because the recipient animal still has intact native heart to support life, the complete rejec tion process can be studied with minimal systemic deteriora tion to the host. In our model, the untreated rats have a sharp decline in allograft cardiac function between POD 5 and 7. Most untreated allograft hearts lose all function by POD 7, and none can survive to POD 8. With this heterotopic trans plantation model, however, the host heart maintains normal circulation and physiology over the entire rejection process, because the native heart supports life. Our findings show that the depletion of macrophages during the course of the experi ment results in markedly improved allograft function and survival. In transplant recipients receiving clodronatelipo somes on days 1, 3, 6, and 8 posttransplantation, the allograft hearts survived to POD 9, with preserved myocardial tissue integrity and cardiac function. There was no sign of func tional deterioration in allograft hearts on PODs 5 to 7 with Figure 6 . Circumferential strain (Ecc) maps of the same allograft hearts over time, derived from tagging MRI for a no treatment allograft heart (A), a PBSliposome-treated allograft heart (B), and a clodronate-liposometreated allograft heart (C). D, Mean Ecc values across the left ventricle wall of the individual hearts shown in A, B, and C on each postoperational day. Blue circles indicate no treatment control allograft heart; red squares, clodronate-liposometreated allograft heart; and green triangles, PBS-liposometreated allograft heart. 3 allograft hearts (B-D) . Untreated isograft and allograft hearts on postoperational day (POD) 7 (A and B) , a clodronate-liposome-treated allograft on POD 7 (C), which reveals decreased damage to the tissue of graft compared with untreated allograft on the same day (B), and a clodronate-liposome-treated allograft on POD 9 (D).
clodronateliposome treatment, and in some cases, cardiac function improved from POD 5 to 7. From PODs 7 to 9, when all allografts from the control groups have failed, clodronate liposome-treated allografts still maintained >80% normal wall motion. Strain values for clodronateliposome-treated allograft hearts showed no statistically significant differences from POD 5 to 9. We chose POD 9 as the end point of this study, because by POD 9 PBStreated allograft hearts have lost myocardial function, exhibiting strains similar to those of no treatment group on POD7, when severe allograft rejection occurred. Additional studies will be needed to determine the longerterm outcome of macrophage depletion. It is important to note that the rats seemed to tolerate the repeated clodronate liposome treatments well, and no adverse effects to the overall rat physiology were noted.
Although clodronateliposomes were developed to deplete mature macrophages, Sunderkötter et al 25 have reported that all circulating monocytes were depleted as well. Our flow cytom etry ( Figure 1 ) and cellular MRI results (Figures 2 and 3) show that ED1 + monocytes and macrophages decrease significantly on clodronateliposome treatment in both circulation and rejecting allograft hearts. In our present study, we began clo dronateliposome treatment 1 day posttransplantation. By this time, there were macrophages present in the graft tissue. In addition to donor resident macrophages within the graft, a high influx of recipient monocytes/macrophages was known to enter graft heart immediately after transplantation in response to the surgical trauma and ischemic reperfusion injury. The subsequent macrophage population was then affected by the recruitment from circulation, exiting, local proliferation, and cell death. This is consistent with recent findings that tissue macrophages have fast turnover kinetics 4 and monocytes/mac rophages are constantly recruited. Other phagocytic cells, such as dendritic cells, could potentially be affected by clodronate liposome treatment as well; however, they are rare in the circu lating hematopoietic mixture but are mobilized into circulation from tissues and organs in response to pathological conditions. About two thirds of clodronateliposome-treated animals did experience an unusual phenomenon, in that a solid mass had developed inside the left ventricle of the transplanted heart, but not seen in the native hearts of same animals. This mass did seem to physically hinder ventricular wall motion and affect strain measurements in some cases; however, these hearts still exhibited better strain values compared with controls and were not excluded from analysis. The size of deposit varied greatly, and the mass was not seen in PBSliposome controls or any native hearts. The source of mass is not known, but preliminary NMR spectroscopy results suggest a lipid compo nent similar to the liposome vehicle used (results not shown). One possibility was that the mass might be an accumulation of macrophage or liposome debris. Frantz et al 26 reported in an experimental myocardial infarction model that clodronate liposome treatment resulted in thrombus formation in left ven tricle. Figure 8 shows the H&E staining of the mass found in transplanted hearts treated with clodronateliposomes. In our model, the mass does not seem to be thrombus; rather, it seems to be layers of lipid. The lack of deposits in PBSliposometreated allografts is consistent with the observation that there is no massive macrophage death, and functional macrophages can clear debris from circulation. A different treatment regi men may mitigate the accumulation of the material in the left ventricle cavity, but this will require further study. Before exploring potential clinical applications, further optimization of clodronateliposome dosing protocol is necessary to better understand and minimize any potential adverse effects, such as the intraventricular mass observed in this study.
It is interesting to note that the PBSliposome-treated group seems to display a slower decline in cardiac function in the earlier phases, compared with the allograft hearts receiving no treatment, but none of the PBSliposome-treated allografts can maintain function beyond POD 8, as observed with clodronate liposome treatment. The fact that the PBSliposome-treated allografts show improvement indicates that liposomes, or certain lipid components of the liposomes, may have beneficial effects for the graft hearts. Alternatively, although PBSliposomes do not deplete macrophages as clodronateliposomes do, the former may temporarily block certain macrophage functions 7 or may affect other systemic or regional immune responses. Further studies are needed to investigate the mechanism of this interesting observation. Nevertheless, PBSliposomes do not preserve allograft hearts against allograft rejection on POD 9 as do clodronateliposomes.
Monocytes and macrophages are centrally involved in mul titude of disorders that have high impact, such as cardiovas cular diseases, cancer, trauma, and autoimmune diseases. 27 Monocytes and macrophages are emerging therapeutic targets in cardiovascular disease; however, clinical tools to assess their presence in tissue are scarce. 4, 28 SPIO and USPIO nanoparti cles can be used to monitor cell movement by in vivo MRI as a function of time. 5, 6 Recently, several studies have reported to have used iron oxide particles to image myocardial inflamma tion in patients with acute myocardial infarction. 29, 30 Clinical translation of cellular MRI to track myocardial inflammation is feasible.
Differences in the affinity of different types of monocytes/ macrophages to different magnetic nanoparticles and contrast agents have been studied recently in ex vivo cell culture sys tems. 31, 32 In our study, we did not discriminate different sub types of macrophages. Further studies are needed to discern if different phenotypes of macrophages possess different in vivo labeling efficiency.
In conclusion, reducing macrophage infiltration in allograft hearts is shown to preserve cardiac tissue, prolong graft survival, and protect dysfunction as a result of acute cardiac rejection. Our results suggest that macrophages in the graft are an essential key trigger for propagating acute allograft rejection cascade and may serve as an in situ biomarker for acute cardiac rejection. Selective elimination of circulating monocytes and macrophages with appropriate timing may be an effective strategy to reduce harmful immune response after transplantation. Additionally, new strategies may be developed to target certain macrophage activities, or inhibiting certain macrophageassociated cyto kines, without completely eliminating them from the body.
